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The CB1 receptor represents a promising target for the treatment of several disorders including 
pain-related disease states. However, therapeutic applications of Δ9-tetrahydrocannabinol (THC) 
and other CB1 orthosteric receptor agonists remain limited because of psychoactive side effects. 
Positive allosteric modulators (PAMs) offer an alternative approach to enhance CB1 receptor 
function for therapeutic gain with the promise of reduced side effects. Here we describe the 
development of the novel synthetic CB1 PAM, 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-
phenyl-1H-indole (ZCZ011), which augments the in vitro and in vivo pharmacological actions of 
the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanolamine (AEA). ZCZ011 
potentiated binding of [3H]CP55,940 to the CB1 receptor as well as enhancing AEA-stimulated 
[35S]GTPγS binding in mouse brain membranes and β-arrestin recruitment and ERK 
phosphorylation in hCB1 cells. In the whole animal, ZCZ011 is brain penetrant, increased the 
potency of these orthosteric agonists in mouse behavioral assays indicative of cannabimimetic 
activity, including antinociception, hypothermia, catalepsy, locomotor activity and in the drug 
discrimination paradigm.  Administration of ZCZ011 alone was devoid of activity in these assays 
and did not produce a conditioned place preference or aversion, but elicited  CB1 receptor 
mediated antinociceptive effects in the chronic constriction nerve injury (CCI) model of 
neuropathic pain and carrageenan model of inflammatory pain. These data suggest that ZCZ011 
acts as a CB1 PAM and provide the first proof of principle that CB1 PAMs offer a promising 
strategy to treat neuropathic and inflammatory pain with minimal or no cannabimimetic side 
effects.  
 
Key words: CB1 receptor; positive allosteric modulator; neuropathic pain; cannabinoid; 







Endocannabinoids (N-arachidonoylethanolamine (anandamide); AEA and 2-
arachidoloylglycerol; 2-AG) are released on demand in response to various stimuli, including 
pain. Through their stimulation of CB1 receptors, they inhibit pain transmission at central, spinal 
and peripheral synapses and may serve an auto protective role (Walker et al, 1999). While 
preclinical data indicate that Δ9-tetrahydrocannabinol (THC), the primary psychoactive 
constituent of Cannabis (Gaoni and Mechoulam, 1964), and other direct CB1 receptor agonists 
are also effective antinociceptive agents in laboratory animal models of neurodegenerative, 
neuroinflammatory and pain-related disease states (Fagan and Campbell, 2014; Guindon and 
Hohmann, 2009; Pryce and Baker, 2012), their distinct cannabimimetic side effect profile, which 
includes abuse, dependence, and memory impairment (Cooper and Haney, 2009; Hampson and 
Deadwyler, 2000; Hutcheson et al, 1998; Justinova et al, 2003; Lichtman et al, 1995), limits 
therapeutic use and further development. Direct agonists, including THC, target the orthosteric 
binding pocket on the CB1 receptor and initiate global activation of the receptor, which is 
heterogeneously expressed in brain, spinal cord and periphery. While endocannabinoids also 
bind orthosterically (Devane et al, 1992; Mechoulam et al, 1995; Sugiura et al, 1995), they are 
released on demand where needed and are quickly metabolized (Di Marzo et al, 1999); hence, 
their actions are more transient and selective with highly specific temporal and spatial regulation.  
Allosteric modulators may offer a similarly selective approach for alteration of CB1 receptor 
signaling, presumably with reduced pharmacodynamic-related side effects. Allosteric modulators 
bind to a distinct, non-orthosteric site on the receptor, and elicit conformational changes that alter 
ligand potency and/or efficacy (Kenakin, 2004, 2013). Accordingly, it has been hypothesized 
that CB1 positive allosteric modulators (PAMs) should enhance antinociceptive and other 
functional effects of endogenously released cannabinoids, but with limited cannabimimetic side 
effects (Pertwee, 2005; Ross, 2007a, b).  
 
Initially reported CB1 receptor allosteric modulators were based on a series of Organon 
compounds, which enhanced orthosteric binding in a ligand-dependent manner, but 
paradoxically, inhibited signal transduction (Price et al, 2005). These, and other allosteric 
modulators of the CB1 receptor, have been characterized on the basis of their actions in 
radioligand binding assays and other functional in vitro assays of CB1 receptor signal 
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transduction (Ahn et al, 2013; Baillie et al, 2013; Horswill et al, 2007; Navarro et al, 2009; 
Pamplona et al, 2012; Piscitelli et al, 2012).  In vivo, the purported negative allosteric modulator 
(NAM), PSNCBAM-1, reduced food intake (Horswill et al, 2007), an action consistent with CB1 
orthosteric antagonism (Di Marzo et al, 2001), although CB1 receptor mediation of this anorectic 
effect was not ascertained.  Another purported CB1 NAM, Org27569, reduced food intake, but 
this effect was CB1 receptor independent (Gamage et al, 2014). Moreover, this compound 
generally failed to modify the pharmacological effects of CB1 orthosteric agonists in common 
rodent models indicative of CB1 receptor activity (Gamage et al, 2014). Likewise, ORG27569 
generally did not perform as a CB1 receptor allosteric modulator in rats (Ding et al, 2014). 
Although it attenuated both cue- and drug-induced reinstatement of cocaine and 
methamphetamine-seeking behavior in rats, CB1 receptor involvement was not determined (Jing 
et al, 2014). The first compelling pharmacological evidence demonstrating the effectiveness of a 
CB1 receptor allosteric modulator in whole animals came from Pamplona et al (2012). They 
found that the endogenous anti-inflammatory mediator, lipoxin A4, enhanced the 
pharmacological effects of AEA at the CB1 receptor both in vitro and in vivo, as well as 
protected against beta-amyloid (1-40)-induced performance deficits in the Morris water maze in 
mice (Pamplona et al, 2012). 
 
In the present study, we examined a novel small molecule CB1 PAM, ZCZ011 (Figure 1a), in in 
vitro and in vivo assays to evaluate whether it behaves as a CB1 PAM. In vitro, ZCZ011 
increased the CB1 receptor agonist receptor binding and potentiated AEA-stimulated signaling in 
[35S]GTPγS binding, β arrestin recruitment, and ERK phosphorylation assays. As there remains a 
tremendous need for new medications to treat chronic pain conditions (Nightingale, 2012), we 
tested whether this compound would reduce nociceptive behavior in the chronic constriction 
injury (CCI) model of neuropathic pain, as well as in the carrageenan model of inflammatory 
pain. Each of these assays is highly sensitive to the antinociceptive effects of orthosteric CB1 
agonists and inhibitors of endocannabinoid catabolic enzymes (Ghosh et al, 2013; Kinsey et al, 
2009; Lichtman et al, 2004; Russo et al, 2007). In addition, we examined ZCZ011 by itself or in 
combination with orthosteric CB1 receptor agonists in a range of common assays sensitive to 
cannabimimetic activity, including the tetrad tests (locomotor activity, antinociception, 
catalepsy, and hypothermia; (Little et al, 1988)) and drug discrimination (Jarbe et al, 1981). 
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Finally, we tested whether systemically administered ZCZ011 was brain penetrant and whether it 
altered endocannabinoid levels in brain.  Here, we demonstrate the first evidence of a CB1 PAM 
that exhibits antinociceptive effects in neuropathic and inflammatory pain models with no 






Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) and male FAAH (−/−) mice, 
backcrossed onto a C57BL/6J background for at least 13 generations served as subjects. FAAH 
(-/-) mice were employed in all experiments examining the in vivo actions of exogenously 
administered AEA to prevent its rapid hydrolysis to arachidonic acid, which is known to produce 
CB1 receptor independent effects (Wiley et al., 2006). While constitutively elevated levels of 
AEA and other lipids in FAAH (-/-) mice might complicate interpretation, it should be noted that 
these mice display normal CB1 receptor expression and function (Cravatt et al., 2001; Lichtman 
et al., 2002; Falenski et al., 2010). All animal protocols were approved by the respective 
Institutional Animal Care and Use Committees at Virginia Commonwealth University and West 
Virginia University and were in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals (National Research Council, 2011).Other details are 
included in the Supplementary Information. 
Materials  
ZCZ011 (6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole) was synthesized at 
University of Aberdeen (see synthesis below). AEA was provided by Organix Inc. (Woburn, 
MA). The pan CB1/CB2 receptor agonist CP55,940, the CB1 receptor antagonist rimonabant [N- 
(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide-HCl] (SR141716A), and the CB2 receptor antagonist SR144528 [5 - (4-chloro- 3-
methylphenyl) - 1- [(4-methylphenyl)methyl] – N - [(1S,2S,4R) - 1,3,3- rimethylbicyclo [2.2.1]  
hept-2-yl]-1H-pyrazole-3- carboxamide] were obtained from the National Institute on Drug 
Abuse Drug Supply Program (Bethesda, MD).  Drugs were dissolved in a vehicle consisting of a 
mixture of ethanol, alkamuls-620 (Sanofi-Aventis, Bridgewater, NJ), and saline (0.9 % NaCl) in 
a ratio of 1:1:18. Each drug was given via the intraperitoneal (i.p.) route of administration with 
exception of the discrimination studies, in which drugs were injected via subcutaneous (s.c.) 
route of administration. All drugs were administered at a volume of 10 μl/g body mass.  
 
Synthesis of ZCZ011 (see Supplementary Information) 
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Mouse brain membrane preparation 
Whole brains from adult male MF1 mice were suspended in centrifugation buffer (320 mM sucrose, 2 
mM EDTA, 5 mM MgCl2) and the tissues were homogenized with an Ultra-Turrex homogenizer. Tissue 
homogenates were centrifuged at 1600 g for 10 min and the resulting supernatant collected. This pellet 
was resuspended in centrifugation buffer centrifuged as before and the supernatant collected. 
Supernatants were combined before undergoing further centrifugation at 28,000 g for 20 min. The 
supernatant was discarded and the pellet resuspended in buffer A (50 mM Tris, 2 mM EDTA, 5 mM 
MgCl2 at pH 7.0) and incubated at 37°C for 10 minutes. Following the incubation, the suspension was 
centrifuged for 20 min at 23,000 g. After resuspending the pellet in buffer A, the suspension was 
incubated for 40 min at room temperature before a final centrifugation for 15 min at 11,000 g. The final 
pellet was resuspended in buffer B (50 mM Tris, 1 mM EDTA, 3 mM MgCl2) and the final protein 
concentration, determined by Bio-Rad Dc kit, was 1 mg ml-1. All centrifugation procedures were carried 
out at 4°C. Prepared brain membranes were stored at -80°C and defrosted on the day of the experiment. 
CHO-hCB1R cells 
CHO cells stably transfected with cDNA encoding human cannabinoid CB1 receptors (see Baillie et al., 
2013) were maintained in Dulbecco’s modified Eagles’s medium (DMEM) nutrient mixture F-12 HAM, 
supplemented with 2mM L-glutamine, 10% fetal bovine serum (FBS), 0.6% penicillin–streptomycin, 
hygromycin B (300µgml-1) and geneticin (600µgml-1). All cells were maintained at 37°C and 5% CO2 in 
their respective media and were passage twice a week using non-enzymatic cell dissociation solution. The 
CHO-hCB1R transfected cell line was used for cAMP and pERK1/2. 
Equilibrium Binding Assays  
Equilibrium binding assays were carried out using [3H]CP55,940, [3H]WIN55212 and 
[3H]SR141716A concentrations of 0.7 nM, 1.2 nM and 1 nM respectively. BSA (1 mg/ml) and 
50 mM Tris buffer was used in a total assay volume of 500 µl containing 0.01% DMSO. Binding 
was initiated by adding 30 µg of mouse brain membranes, as previously described (Baillie et al, 
2013). Assays were incubated at 37°C for 60 min, and then the reaction was stopped by the 
addition of ice cold wash buffer that contained 50 mM Tris buffer and 1 mg/ml BSA and vacuum 
filtration using a 24-well sampling manifold Brandel cell harvester (Gaithersburg, MD). Specific 
binding is defined as the difference between the binding that occurred in the presence and 




[35S]GTPγS Binding Assay 
Mouse brain membranes (5 µg protein) were preincubated for 30 min at 30°C with adenosine 
deaminase (0.5 U ml-1). The membranes were then incubated with the agonist ± modulator or 
vehicle for 60 min at 30°C in assay buffer (50 mM Tris; 5 mM MgCl2; 1 mM EDTA; 100 mM 
NaCl; 1 mM DTT; 0.1% BSA) in the presence of 0.1 nM [35S]GTPγS and 30 µM GDP.  Binding 
was initiated by the addition of [35S]GTPγS. Nonspecific binding was measured in the presence 
of 30 µM GTPγS. The reaction was terminated by rapid vacuum filtration (50 mM Tris-HCl; 
50 mM Tris-Base; 0.1 % BSA) using a 24-well sampling manifold (cell harvester; Brandel, 
Gaitherburg, MD) and GF/B filters (Whatman, Maidstone, UK). 
Data Analysis: Raw data were presented as cpm. Basal level was defined as zero. Results were 
calculated as a percentage change from basal level of [35S]GTPγS binding (in the presence of 
vehicle). Data were analysed by nonlinear regression analysis of sigmoidal dose response curves 
using GraphPad Prism 5.0 (GraphPad, San Diego, CA). The results of this analysis are presented 
as Emax with 95% confidence limits and pEC50 (logEC50) ± SEM. 
 
PathHunter® CB1 β-Arrestin Assays 
PathHunter® hCB1 β-arrestin cells were plated 48 h before use and incubated at 37°C, 5% CO2.  
Compounds were dissolved in DMSO and diluted in OCC media. 5 µl of allosteric modulator or 
vehicle solution was added to each well and incubated for 60 min. 5 µl of agonist was added to 
each well followed by a 90 min incubation. 55 µl of detection reagent is then added followed by 
further 90 min incubation at room temperature. Chemiluminescence, indicated as RLU, was 
measured on a standard luminescence plate reader. 
Data Analysis: Raw data were relative light units (RLU). Basal level was defined as zero. 
Results were calculated as the percentage of CP55940 maximum effect. Data were analyzed by 
nonlinear regression analysis of sigmoidal dose response curves using GraphPad Prism 5.0 
(GraphPad, San Diego, CA). The results of this analysis are presented as Emax with 95% 
confidence limits and pEC50 (logEC50) ± SEM. 
 
AlphaScreen® SureFire® ERK 1/2 phosphorylation assay  
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ERK1/2 MAP-kinase phosphorylation assay. For experimental studies of ERK1/2 MAP-kinase 
phosphorylation, hCB1R cells (40,000 cells/well) were plated onto 96 well plates and serum-
starved for 24 h.  Cells were then washed with DMEM before the addition of agonist ± Org 
27569 or vehicle at the desired concentration. After a 6 minute incubation at 37ºC in a 
humidified atmosphere, ice cold lysis buffer (provided with the AlphaScreen® SureFire® kit) 
was added to each well and the plate was placed at -80°C for at least 1 hour.  
AlphaScreen® SureFire® ERK Assay. The assay was performed in 384 well white Proxiplates 
according to the manufacturer instructions. Briefly, 4 μl samples were incubated with 7 μl of 
mixture containing: 1 part donor beads: 1 part acceptor beads: 10 parts activation buffer: 60 parts 
reaction buffer. Plates were incubated for 3 hours at 25°C in the dark and read with the 
Envision® system (PerkinElmer) using AlphaScreen® settings.  
Data Analysis. Raw data were presented as ‘Envision units’. Basal level was defined as zero. 
Results were presented as means and variability as SEM or 95% confidence limits (CL) of the 
percent stimulation of phosphorylated ERK1/2 above the basal level (in the presence of vehicle). 
Data were analyzed by nonlinear analysis of log agonist versus-response curves using GraphPad 
Prism 5.0 (GraphPad, San Diego, CA). The results of this analysis were presented as Emax with 
95% confidence limits and pEC50 (logEC50) ± SEM. 
 
DiscoverX® cAMP Assays 
For experimental studies of inhibition of cAMP formation, hCB1R cells (20,000 cells/well) were 
plated into 96 well plates and serum-starved for 24 h. Cells were then washed with serum and 
phenol free DMEM before the addition of agonist with vehicle/allosteric modulator in the 
presence of 10µM rolipram and 10µM forskolin. Cells were stimulated for 30 minutes at 37°C in 
a humidified atmosphere.   The DiscoverX® cAMP kit was then used and a standard curve was 
included in every assay. Antibody solution was added to each well followed by working 
solution: 1 part ED solution and 1 part combination- lysis (19), Emerald solution (5) and Gal (1). 
Plates were incubated at room temperature for 60 minutes. A final addition of EA reagent to each 
well was followed by incubation at room temperature for no less than 3 but no more than 18 
hours and plates were read using a luminescence plate reader.  
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Data Analysis: Results were calculated as the percentage inhibition of forskolin-stimulated 
cAMP production. Data were analyzed by nonlinear regression analysis of sigmoidal dose 
response curves using GraphPad Prism 5.0 (GraphPad, San Diego, CA). The results of this 
analysis were presented as Emax with 95% confidence limits and pEC50 (logEC50) ± SEM. 
 
 
Chronic Constriction Nerve Injury (CCI) Model of Neuropathic Pain 
CCI nerve injury was induced according to surgical procedures described previously (Kinsey et 
al, 2009), as detailed in supplementary methods.  ZCZ011 (0, 10, 20, 40 mg/kg) was injected via 
the i.p. route of administration and mice were tested for mechanical and cold allodynia 75 min 
later.  ZCZ011 was administered in a counterbalanced Latin square within subject design with at 
least a five day wash out period between tests.  In order to assess the effects of repeated 
treatment of ZCZ011 (40 mg/kg, i.p.) on mechanical and cold allodynia induced by CCI, mice 
were divided into the following three experimental groups: 1) Vehicle Control (six days of 
vehicle injections); 2) Acute ZCZ011 (five days of vehicle injections and injected with 40 mg/kg 
ZCZ011 on day 6); and 3) Repeated ZCZ011 (six days of injections of 40 mg/kg ZCZ011). In 
the repeated ZCZ011 group, mechanical and cold allodynia were assessed 1, 2, 4, 12 and 24 h 
following the first ZCZ011 injection to determine duration of acute anti-allodynic effects of 
ZCZ011. The subjects in all groups were tested 1 h following ZCZ011 administration on day 6. 
In experiments assessing cannabinoid receptor mechanism of action, rimonabant (3 mg/kg) or 
SR144528 (3 mg/kg) was administered 10 min prior to ZCZ011 or vehicle. Mechanical allodynia 
was assessed using von Frey filaments and the acetone flinching test was used to assess cold 
allodynia, as described previously (Kinsey et al, 2009) and detailed in Supplementary 
Information.  
 
Carrageenan Model of Inflammatory Pain 
Edema was induced via intraplantar injection of 0.3 % carrageenan (Sigma, St Louis, MO) in a 
20 µl volume using a 30 gauge needle into the hind left paw. Paw thickness was measured with 
an electronic digital micrometer (Traceable Calipers, Friendswood, TX) prior to and 5 h 
following carrageenan administration, which corresponds to peak edema (Wise et al, 2008). Paw 
edema data are expressed as the difference in paw thickness between the 5 h and pre-injection 
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measures. Mechanical allodynia was assessed using von Frey filaments at the same peak time 
point (see Supplementary Information).   
 
Tetrad Assay 
The behavioral testing was conducted in the following order: bar test (catalepsy), tail withdrawal 
test, and rectal temperature. A separate group of mice was used to assess the effects of ZCZ011 
on locomotor activity. Testing was performed according to previously described procedures 




Male C57BL/6J and FAAH (-/-) mice (20–25 g) trained to discriminate CP55,940 (0.1 mg/kg) or 
AEA (6 mg/kg) from vehicle, respectively, were tested in a nose-poke operant task according to 
procedures described previously (Long et al, 2009b) with minor modifications. For complete 
description of these procedures, see Supplementary Information.   
 
ZCZ011 Place Conditioning 
An unbiased mouse CPP paradigm was utilized, as previously described (Kota et al, 2008) in 
which vehicle, ZCZ011 (40 mg/kg), or cocaine (10 mg/kg; positive control) were randomly 
paired with one of two distinct chambers. On the test day, mice did not receive an injection and 
were allowed to roam freely for 15 min while the percentage of time spent in both chambers was 
scored as the dependent measure. For further details, see Supplementary Information. 
 
Extraction and Quantification of Endocannabinoids by Liquid Chromatography-tandem 
Mass Spectrometry (see Supplementary Information) 
C57BL/6J mice were administered ZCZ011 (40 mg/kg) either acutely and sacrificed 45 min 
later. Brains were harvested and the concentrations of 2-AG, AEA, palmitoylethanolamide 
(PEA), oleoylethanolamide (OEA) and arachidonic acid (AA) levels were quantified, as 






All in vivo data are presented as mean ± standard error (SEM) or 95 % confidence limits (CL). 
In vitro data were analysed using log agonist versus response curves in GraphPad Prism 5.0 
(GraphPad, San Diego, CA). The results of this analysis were presented as Emax with 95 % 
confidence limits and pEC50 (logEC50) ± SEM.  In vivo data were analyzed using one-way or 
two-way analysis of variance (ANOVA). Dunnett's test was used for post hoc analysis in the 
dose-response experiments, and the Tukey test was used for post hoc analyses comparing 
different treatment groups. Multiple comparisons following two-way ANOVA were conducted 
with Bonferroni post hoc comparisons. Differences were considered significant at the level of 






ZCZ011 Enhanced CB1 Receptor Agonist Binding 
In equilibrium binding experiments, ZCZ011 (Figure 1a) produced a significant and 
concentration-dependent increase in the specific binding of the CB1 receptor orthosteric agonist, 
[3H]CP55,940 to mouse brain membranes with an Emax of 207 % (95 % confidence limits, 191-
223) and a pEC50 of 6.90 ± 0.23 (Figure 1b).  ZCZ011 also produced a significant and 
concentration-dependent increase in the specific binding of the CB1 receptor orthosteric agonist, 
[3H]WIN55212 to mouse brain membranes with an Emax of 225 % (95 % confidence limits, 182-
269) and a pEC50 of 6.31 ± 0.33 (Figure 1b).  In contrast, ZCZ011 produced a significant and 
concentration-dependent decrease in the specific binding of the CB1 receptor orthosteric inverse 
agonist, [3H]SR141716A to mouse brain membranes with an Emax of 17 % (95 % confidence 
limits, -2.7 - 37) and a pEC50 of 6.21 ± 0.21 (Figure 1b).   
 
In saturation binding experiments, [3H]CP55,940 bound in a saturable manner to the CB1 
receptor with a Bmax of 1.37 pmol/mg (95 % confidence limits, 1.042 – 1.704) and Kd of 3.10 ± 
0.9 nM (Figure 1c). ZCZ011 (1 µM) significantly increased the Bmax value of [
3H]CP55,940 to 
1.88 pmol/mg (95 % confidence limits, 1.728-2.025) without significantly affecting binding 
affinity (Kd = 1.97 ± 0.2 nM; Figure 1c), suggesting an increase in the number of available 
binding sites for [3H]CP55,940.   
 
ZCZ011 Enhanced CB1 Receptor Agonist Signalling 
[35S]GTPγS binding 
AEA stimulated [35S]GTPγS binding in mouse brain membranes with a pEC50 value of 6.5 ± 0.2 
and Emax (efficacy) of 46.5% (95% confidence limits, 40-54; Figure 1d). Addition of 100 nM 
ZCZ011, significantly enhanced AEA-stimulated [35S]GTPγS binding [Emax of 115.2% (95% 
confidence limits, 104 - 127)], but there was no significant change in the pEC50 value (potency). 
A concentration of 10 nM ZCZ011 enhanced AEA-stimulated [35S]GTPγS binding with an Emax 
of 65.4% (95% confidence limits, 51-80); however, this effect was not statistically significant. 
ZCZ011 alone caused no stimulation of [35S]GTPγS binding. 
Similarly, CP55,940 stimulated [35S]GTPγS binding in mouse brain membranes with a pEC50 
value of 8.34 ± 0.25 and Emax of 61% (95% confidence limits, 50-72) (Supplementary Figure 
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1a). Addition of 1µM ZCZ011, significantly enhanced AEA-stimulated [35S]GTPγS binding 
[Emax of 100% (95% confidence limits, 82 – 112)], but there was no significant change in the 
pEC50 value (8.80 ± 0.26).  
 
PathHunter® hCB1 β-arrestin recruitment assay 
In the PathHunter® β-arrestin assay in hCB1 cells, AEA stimulated β-arrestin recruitment with a 
pEC50 of 6.1 ± 0.10 and an Emax of 100% (95% confidence limits, 87-113; Figure 1e). ZCZ011 
caused a concentration dependent enhancement of AEA-stimulated β-arrestin recruitment at 10 
nM, 100nM and 1µM with Emax values of 99% (95% confidence limits, 90-107) and 157% (95% 
confidence limits, 138-175) and 195% (95% confidence limits, 185-205), respectively. There 
was no significant change to the pEC50 value of 6.78 ± 0.11 and 7.02 ± 0.12 in the presence of 10 
nM and 100 nM ZCZ011, respectively.  At 1 nM AEA, the maximum stimulation observed was 
0.0% (95% confidence limits, -6.6 – 6.6); however, the addition of 10 nM, 100 nM  and 1μM 
ZCZ011 significantly increased stimulation to 18.1% (95% confidence limits, 10.8 – 25.4), 
65.1% (95% confidence limits, 47 – 83) and 161.6% (95% confidence limits, 148 – 175), 
respectively. These findings indicate positive cooperativity between the endogenous cannabinoid 
and ZCZ011. When tested alone, ZCZ011 produced an increase in β-arrestin recruitment that 
was 35.9% (95% confidence limits, 33-39) of maximal stimulation. 
 
AlphaScreen® surefire® ERK 1/2 phosphorylation assay 
Using an AlphaScreen® surefire® ERK 1/2 phosphorylation assay kit, we measured the effect of 
ZCZ011 on activation of ERK 1/2 phosphorylation by CB1 agonist, AEA in hCB1R cells (Figure 
1f). AEA induced ERK 1/2 phosphorylation with an Emax of 98.2% (95% confidence limits, 79-
118) and pEC50 of 6.5 ± 0.3. Neither 10 nM nor 100 nM ZCZ011 significantly affected AEA 
Emax (efficacy), but pEC50 value (potency) was significantly increased to 8.3 ± 0.3 and 8.4 ± 0.5, 
respectively (one-way ANOVA, Dunnett’s multiple comparison test, p < 0.05). With the 
exception of the highest concentration (1 µM), ZCZ011 alone did not induced ERK 1/2 
phosphorylation.  
 
CP55,940 induced ERK 1/2 phosphorylation with an Emax of 101% (95% confidence limits, 86-
116) and pEC50 of 7.85± 0.25 (Supplementary Figure 1b). 1µM ZCZ011 did not affect the Emax 
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(efficacy) of CP55,940 [Emax of 119% (95% confidence limits, 107-132)] but pEC50 value 
(potency) was significantly increased to 8.95 ± 0.3 (one-way ANOVA, Dunnett’s multiple 
comparison test, p < 0.05).  
 
DiscoverX® hCB1 cAMP production assay 
Using a DiscoverX® cAMP production assay, we measured the effect of ZCZ011 on activation 
of ERK 1/2 phosphorylation by CB1 agonist, AEA in hCB1 cells (Figure 1g). AEA inhibited 
forskolin stimulated cAMP production with an Emax of 59% (95% confidence limits, 35-83) and 
pEC50 of 6.97 ± 0.35. Alone, ZCZ011 acted as an agonist; inhibiting forskolin stimulated cAMP 
production with an Emax of 84% (95% confidence limits, 46-122) and pEC50 of 5.68 ± 0.33. 100 
nM ZCZ011 did not significantly affected AEA. There was evidence positive cooperatively at a 
concentration of 1μM ZCZ011. 
 
CP55,940 inhibited forskolin stimulated cAMP production with an Emax of 83% (95% confidence 
limits, 75 - 92) and pEC50 of 8.27 ± 0.13. 100 nM ZCZ011 did not significantly affected AEA. 
1μM ZCZ011 did not significantly affect the Emax or pEC50 of CP55,940 (Supplementary 
Figure 1c).  
 
 
ZCZ011 Does Not Produce Psychoactive Effects in Mice 
ZCZ011 (40 mg/kg) was detected in whole brain, 6.5 + 0.6 (mean + SEM) ng/wet (g), as 
determined by HPLC/MS/MS (Poklis et al, in press).  Given alone, 40 mg/kg ZCZ011 did not 
produce catalepsy (0s immobility), hypothermia (p = 0.4; Supplementary Figure 2a), 
antinociception in tail withdrawal  (p = 0.9; Supplementary Figure 2b) or hot plate tests (p = 
0.8; Supplementary Figure 2c) , or locomotor depression (p = 0.9; Supplementary Figure 2d). 
ZCZ011 did not substitute for either CP55,940 (Supplementary Figure 2e) or AEA 
(Supplementary Figure 3a) in the drug discrimination assay and did not affect respective 
response rates for either training drug (p = 0.9; Supplementary Figure 2f and p = 0.9, p = 0.1; 
Supplementary Figure 3b). Also, ZCZ011 (40 mg/kg) did not elicit a conditioned place 




ZCZ011 Potentiates the Pharmacological Effects of AEA and CP55,940 in Mice 
In contrast to its ineffectiveness to elicit cannabimimetic effects when administered alone, 
ZCZ011 significantly augmented the antinociceptive [F(1,14)=8.0, p<0.01], cataleptic 
[F(2,28)=3.84, p<0.05], and  hypothermic [F(1,14)=5.5; p<0.05] effects of CP55,940 (Figure 
2a-c). It also enhanced AEA-induced hypothermia [F(4,64)=2.93; p<0.05; Figure 2d], but did 
not affect the antinociceptive (p=0.8; Figure 2e) or cataleptic (p=1; Figure 2f) effects of AEA in 
FAAH (-/-) mice. Also, this compound did not alter the antinociceptive effects of 1 mg/kg 
nicotine (Supplementary Figure 5). 
 
In the drug discrimination assay, ZCZ011 (40 mg/kg) significantly increased the potency of the 
discriminative stimulus effects of AEA in FAAH (-/-) mice [F(4,48)=10.47, p<0.001; 
Supplementary Figure 3a]. The respective ED50 (95% CI) values of AEA in the vehicle-
pretreated mice and ZCZ011-pretreated mice were 4.0 (2.7-5.9) mg/kg and 1.4 (1.2-1.7) mg/kg. 
ZCZ011 increased AEA potency 2.2-fold compared with the vehicle-pretreated mice. ZCZ011 
(20 mg/kg) also significantly enhanced the discriminative cue of AEA. While ZCZ011 (40 
mg/kg) given alone or in combination with AEA did not affect response rates of FAAH (-/-) 
mice in the drug discrimination paradigm (Supplementary Figure 3b), it potentiated the 
depressive effects of AEA (5.6 mg/kg) on operant responding for food in a separate group of 
mice [F(1,4)=6.88, p<0.05; Supplementary Figure 6]. 
 
ZCZ011 Reverses Nociceptive Behavior in Neuropathic and Inflammatory Pain Models 
ZCZ011 enhanced the pharmacological effects of AEA and CP55,940 in in vitro and in 
behavioral assays, but did not produce common cannabimimetic effects on its own. Accordingly, 
we next investigated whether it would reverse nociceptive behavior in well-established models of 
neuropathic and inflammatory pain. As has been previously shown (Kinsey et al, 2010), the 
FAAH inhibitor, PF-3845 reversed mechanical (Figure 3a) and cold allodynia (Figure 3b) in the 
CCI model of neuropathic pain.  These findings are consistent with the idea that AEA, which is 
rapidly hydrolyzed by FAAH, has an autoprotective role in this model. Similarly, ZCZ011 
completely reversed mechanical [F(3,42)=7.6, p<0.001; Figure 3a] and cold allodynia 
[F(3,42)=3.6, p<0.05; Figure 3b] in the CCI model of neuropathic pain. Unlike endocannabinoid 
catabolic enzyme inhibitors; however, ZCZ011 (40 mg/kg) did not affect whole brain levels of 2-
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AG (p=0.3), AEA (p=0.3), palmitoylethanolamide (p=0.3), or oleoylethanolamide (p=1) in 
C57BL/6J mice (Supplementary Figure 7). 
 
These anti-allodynic actions of ZCZ011 were prevented by the CB1 receptor antagonist, 
rimonabant (3 mg/kg), but not by the CB2 receptor antagonist, SR144528 (3 mg/kg), 
[F(3,28)=8.9, p<0.001; Figure 3c and d], indicating a CB1 receptor-mediated mechanism of 
action.  
 
ZCZ011 (40 mg/kg) blocked mechanical allodynia [F(4,56)=6.0, p<0.001] and cold allodynia 
[F(4,56)=4.44, p<0.01; Figure 4a and b] for durations of 12 h and 4 h, respectively. The anti-
allodynic effects of ZCZ011 (40 mg/kg) to mechanical [F(2,21)=8.9, p<0.01; Figure 4c] and 
cold [F(2,21)=7.0, p<0.01; Figure 4d] stimuli were retained following six days of daily 
injections and did not differ from the antinociceptive effects produced by acute ZCZ011. Thus, 
the antinociceptive effects of ZCZ011 were resistant to tolerance. 
 
Likewise, ZCZ011 (40 mg/kg) partially reversed carrageenan-induced mechanical allodynia 
[F(2,21)=22.3, p<0.001; Figure 5a], which required CB1, receptors, but not CB2 receptors 
[F(1,16)=14.7, p<0.01; Figure 5b]. Consistent with its lack of CB2 receptor action, ZCZ011 did 







Here we report the development and pharmacological characterization of the novel synthetic CB1 
receptor PAM, ZCZ011. This compound increased equilibrium binding of the potent CB1 
receptor orthosteric agonist, CP55,940. Additionally, ZCZ011 enhanced the efficacy of AEA in 
stimulating [35S]GTPS binding in whole brain as well as β-arrestin recruitment and the potency 
of AEA in ERK phosphorylation assays in hCB1 cells. In mice, ZCZ011 potentiated CP55,940-
induced catalepsy, hypothermia, and antinociception. It also increased the potency of AEA in 
several in vivo assays employing FAAH (-/-) mice, including the discriminative stimulus effects 
of AEA, AEA-induced depression of operant responding for food, and AEA-induced 
hypothermia. Most strikingly, when administered alone, ZCZ011 completely reversed allodynia 
in the CCI model of neuropathic pain and partially reversed carrageenan-induced allodynia, but 
did not elicit any apparent cannabimimetic side effects. Its actions in the CCI model required 
CB1 receptors, were of long duration (i.e., up to 12 h), and did not undergo tolerance after six 
days of treatment. Accordingly, we hypothesize that ZCZ011 blocked neuropathic pain, without 
eliciting general cannabimimetic activity, by augmenting the actions of endocannabinoids at CB1 
receptors in pathways mediating nociceptive responses following sciatic nerve injury. Likewise, 
ZCZ011 reduced carrageenan-induced allodynia through a CB1 receptor mechanism of action, 
and did not reduce the edematous effects of carrageenan. Thus, this study provides compelling 
parallel in vitro and in vivo evidence that ZCZ011 acts as a CB1 receptor PAM.  Accordingly, 
ZCZ011 represents a valuable pharmacological tool for mechanistic studies as well as for 
exploring potential therapeutic applications of CB1 receptor allosteric target(s).    
 
Our in vivo observations showing that ZCZ011 potentiated the pharmacological effects of either 
CP55,940 or AEA in behavioral assays confirm in vitro observations showing that ZCZ011 acts 
as a CB1 PAM and enhances the signalling of the bound agonist. ZCZ011 (1 µM) caused an 
increase in the Bmax of [
3H]CP55,940 and [3H]WIN55212, which implies an increase in the 
number of available receptors for CP55,940 to bind. Intriguingly, ZCZ011 elicited an apparent 
displacement of the CB1 receptor inverse agonist, SR141716A. With the exception of cAMP 
activity, ZCZ011 increased CB1 orthosteric agonist potency and/or efficacy in all the functional 
assays performed. Specifically, ZCZ011 potentiated AEA and CP55,940 signaling efficacy in the 
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[35S]GTPS binding in mouse brain membranes and increased the potency of AEA and 
CP55,940 in the ERK phosphorylation assay in hCB1 cells, and enhanced the potency of AEA-
mediated β-arrestin recruitment. This evidence strongly suggests that ZCZ011 acts as a CB1 
PAM both in vitro and in vivo. In the cAMP assay, ZCZ011 acted as an agonist alone, but did not 
affect the potency or efficacy of AEA or CP55,940 at a concentration of 1μM. 
 
A highly novel finding in the present study was that ZCZ011 produced anti-allodynic effects in 
CCI model of neuropathic pain. Previous studies have also demonstrated that the anti-allodynic 
effects of FAAH inhibitors (Kinsey et al, 2010; Kinsey et al, 2009), as well as MAGL inhibitors 
JZL184 and KML29 (Ignatowska-Jankowska et al, 2014; Kinsey et al, 2010; Kinsey et al, 2009) 
elicited anti-allodynic effects in the CCI assay. Repeated administration of high dose ZCZ011 
retained its antinociceptive effects, which is similar to the finding that the antinociceptive effects 
produced by FAAH inhibition also do not undergo tolerance (Schlosburg et al, 2010). While 
repeated high doses of MAGL inhibitors leads to antinociceptive tolerance associated with CB1 
receptor down-regulation and desensitization (Ignatowska-Jankowska et al, 2014; Schlosburg et 
al, 2010), CB1 receptor function is retained following repeated low doses of the MAGL inhibitor 
JZL184 (Kinsey et al, 2013; Sciolino et al, 2011). The most notable difference between ZCZ011 
and endocannabinoid catabolic enzyme inhibitors is that ZCZ011 did not alter the concentration 
of endocannabinoids or other N-acylethanoloamines in brain (Supplementary Figure 7). In 
contrast, FAAH and MAGL inhibitors produce increased brain levels of AEA (Kathuria et al, 
2003) and 2-AG (Long et al, 2009a), respectively. The anti-allodynic effects of ZCZ011 in the 
CCI assay, were CB1, but not CB2, receptor dependent. In contrast, FAAH inhibitors require both 
CB1 and CB2 receptors to reverse CCI-induced allodynia (Kinsey et al, 2010; Kinsey et al, 
2009). Additionally, FAAH (Holt et al, 2005) and MAGL (Ghosh et al, 2013) inhibitors produce 
anti-edematous actions in the carrageenan assay, which in each case was completely blocked by 
a CB2 receptor antagonist and not a CB1 receptor antagonist. Thus, a CB1 PAM would not be 
expected to reduce carrageenan-induced paw edema, as the case in the present study. 
Collectively, these findings are consistent with the idea that the anti-allodynic effects of ZCZ011 
in the CCI and carrageenan assays are mediated through its actions as a CB1 PAM by enhancing 




An important observation from a drug development perspective is that ZCZ011 did not produce 
cannabimimetic side effects (i.e., catalepsy, hypothermia, thermal antinociception, or 
hypomotility) and did not substitute for AEA or CP55,940 in the drug discrimination paradigm. 
However, ZCZ011 enhanced many pharmacological effects produced by these orthosteric 
agonists, consistent with in vitro data showing that it acts as a CB1 receptor PAM. While it is 
interesting that ZCZ011 augmented more of the measured actions produced by CP55,940 than 
those elicited by AEA, it is known that allosteric modulators affect orthosteric agonists in a 
ligand-dependent manner. The failure of ZCZ011 to affect nicotine-induced antinociception in 
the tail withdrawal and hot plate tests (Supplementary Figure 5) shows that its effects are 
selective to cannabinergic ligands.   
 
Pamplona et al. (2012) presented the first in vivo and in vitro evidence demonstrating that the 
endogenous anti-inflammatory mediator, lipoxin A4, acts as a CB1 PAM. This naturally 
occurring lipid enhanced both CB1 receptor binding of AEA and AEA-induced cAMP inhibition.  
Moreover, when given via the i.c.v. route of administration lipoxin A4 produced cannabimimetic 
effects (i.e., catalepsy, hypothermia, hypomotility, and antinociceptive effects in the hotplate 
test). Notably, systemic administration of an inhibitor of 5-lipoxygenase, the primary 
biosynthetic enzyme of lipoxin A4, attenuated the cataleptic effects of i.c.v administered AEA, 
suggesting that this endogenous lipid contributes to the behavioral actions of CB1 orthosteric 
agonists.  In addition, i.c.v. administration of lipoxin A4 protected mice from impaired spatial 
memory performance in the Morris water maze task elicited by i.c.v. injection of β-amyloid (1-
40) protein. This protective effect was blocked by rimonabant, indicating a CB1 receptor-
mediated mechanism of action.  The data presented here with ZCZ011, together with those 
previously published with lipoxin A4 (Pamplona et al, 2012), provide compelling proof of 
principle that CB1 PAMs offer promise as therapeutic strategies for neurodegenerative diseases 
and pain states related to nerve injury. The identification of the putative binding site(s) of 
ZCZ011 and lipoxin A4 at the CB1 receptor will be a crucial step for future development of 
allosteric modulators of the CB1 receptor as well as better understanding of the physiological 
function of CB1 allosteric modulation for the development of novel pharmacotherapies based on 
this mechanism. Nonetheless, the present study demonstrates that the synthetic CB1 PAM, 
ZCZ011, produces CB1-mediated anti-allodynic effects in murine models of neuropathic and 
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inflammatory pain without the development of tolerance or the occurrence of cannabimimetic 
side effects. 
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Figure legends  
 
Figure 1: The CB1 positive allosteric modulator, ZCZ011 enhances CB1 receptor binding 
and signaling (a) Chemical structure of ZCZ011. (b) ZCZ011 significantly increased 
[3H]CP55,940 binding in mouse brain membranes. (c) ZCZ011 caused a significant increase in 
the Bmax for [
3H]CP55,940 and [3H]WIN55212 whilst having no effect on the Kd. ZCZ011 
caused an apparent displacement of [3H]SR141617A. (d) ZCZ011 caused a significant increase 
in the efficacy of AEA-stimulated [35S]GTPγS binding in mouse brain membranes. (e) ZCZ011 
caused a significant increase in AEA-stimulated -arrestin recruitment in hCB1 cells. (f) ZCZ011 
caused a significant increase in the potency of AEA to stimulate ERK 1/2 phosphorylation in 
hCB1 expressing cells. (g) Effect of ZCZ011 on forskolin-stimulated cAMP production in hCB1 
expressing cells; ZCZ011 alone inhibits forskolin-stimulated cAMP production. Symbols 
represent mean values ± S.E.M from 2-7 independent experiments.  
 
Figure 2: ZCZ011 (40 mg/kg) potentiated the pharmacological effects of orthosteric CB1 
receptor agonists CP55,940 and AEA. ZCZ011 significantly enhanced CP55,940-induced 
hypothermia (a), catalepsy (b), and antinociception (c) in C57BL/6J mice and AEA-induced 
hypothermia (d), but not AEA-induced catalepsy (e) or antinociception (f), in FAAH (-/-) mice. 
Data presented as mean ± SEM; n = 8-9 mice per group; * p < 0.05, ** p < 0.01, *** p < 0.001 
vs vehicle. 
 
Figure 3: ZCZ011 significantly reduced mechanical (a) and cold (b) allodynia induced by 
chronic constriction nerve injury (CCI). The anti-allodynic effects of ZCZ011 (40 mg/kg, i.p.) 
were blocked by the CB1 receptor antagonist rimonabant (SR141716A, SR1) (3 mg/kg; c), but 
not by the CB2 receptor antagonist SR144528 (SR2) (3 mg/kg; d). The FAAH inhibitor, PF-3845 
(10 mg/kg, i.p.) was included for comparison. Results presented as mean ± SEM; (n = 9-12 mice 





Figure 4. The anti-allodynic effects of ZCZ011 (40 mg/kg) are of long duration and do not 
undergo tolerance after six days of daily injections in the CCI model of neuropathic pain. 
ZCZ011 significantly reversed mechanical allodynia for up to 12 h (a) and cold allodynia for up 
to 4 h (b). The anti-allodynic effects of ZCZ011 are retained following six days of repeated 
administration in response to tactile (c) and cold (d) stimulation. Values represent mean ± SEM, 
n=8 mice per group, *p<0.05, **p<0.01, ***p<0.001 vs vehicle, $$p<0.01, $$$p<0.001 vs. 
contralateral paw.  
 
Figure 5: ZCZ011 partially reversed mechanical allodynia in the carrageenan model of 
inflammatory pain. The CB1 receptor antagonist rimonabant (SR141716A, SR1; 3 mg/kg, a), 
but not the CB2 receptor antagonist SR144528 (SR2; 3 mg/kg; b) blocked the anti-allodynic 
effects of ZCZ011. Results presented as mean ± SEM; (n = 9-12 mice per group). ZCZ011 (40 
mg/kg, i.p.) did not attenuate carrageenan-induced paw edema (c and d). Values represent mean 
± SEM, n=8 mice per group.*p<0.05, **p<0.01, ***p<0.001, ###p<0.001 vs vehicle; $$p<0.01, 
$$$p<0.001 vs. contralateral paw. 
 
Supplementary Figure 1: ZCZ011 (ZCZ) affects the signaling of the orthosteric CB1 receptor 
agonist, CP55,940 (CP). (a) ZCZ011 caused a significant increases the efficacy of CP55-
stimulated [35S]GTPγS binding in mouse brain membranes. (b) ZCZ011 caused a significant 
increase in the potency of CP55 to stimulate ERK 1/2 phosphorylation in hCB1 CHO expressing 
cells. (c) ZCZ011 (1 μM) did not significantly affect the potency or efficacy of CP55 to inhibit 
forskolin-stimulated cAMP production in hCB1 expressing cells. Symbols represent mean values 
± S.E.M from 2-4 independent experiments.  
 
Supplementary Figure 2: ZCZ011 does not produce cannabimimetic effects when given 
alone. ZCZ011 (40 mg/kg, 15 min pretreatment) did not affect thermal antinociception in (a) the 
warm water tail withdrawal and (b) hot plate tests, did not affect (c) body temperature (d) did not 
elicit locomotor depression and (e) did not substitute for CP55,940 or (f) depress response rates 
in the drug discrimination assay. Also, ZCZ011 did not produce catalepsy (0 s immobility time). 





Supplementary Figure 3: (a) ZCZ011 significantly increased the AEA potency as a 
discriminative stimulus in FAAH (-/-) mice, but did not affect response rates (b).  Data presented 
as mean ± SEM; n = 8-9 mice per group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs vehicle.  
 
Supplementary Figure 4: ZCZ011 [40 mg/kg, i.p.] did not produce a conditioned place 
preference or conditioned place aversion. In contrast, cocaine (10 mg/kg), which served as a 
positive control, produced a significant place preference [F(2,23)=8.9, p<0.01. Data are 
presented as mean ± SEM, n = 7-10 mice per group. *p < 0.05 vs. vehicle, ##p<0.01 vs. cocaine. 
 
Supplementary Figure 5: ZCZ011 (40 mg/kg, i.p., 45 min pretreatment) did not affect nicotine-
induced antinociception in tail withdrawal (a) or hot plate (b) tests. Data presented as 
mean ± SEM, n = 8 mice per group. 
 
Supplementary Figure 6: ZCZ011 (40 mg/kg) significantly potentiated the rate-suppressing 
effects of AEA (5.6 mg/kg) in a nose-poke operant procedure for food reinforcement. When 
given alone ZCZ011 (40 mg/kg, i.p.) or AEA (5.6 mg/kg, s.c.) did not alter operant responses 
compared with the vehicle controls.  Mean ± SEM, n = 8-10 mice per group, *p < 0.05 vs. each 
other group. 
 
Supplementary Figure 7: ZCZ011 (40 mg/kg, i.p.) did not affect whole brain levels of (a) 2-
arachidonoylglycerol (2-AG), (b) anandamide (AEA), (c) palmitoylethanolamide (PEA), or 
(d) oleoylethanolamide (OEA) in C57BL/6J mice. Data presented as mean ± SEM, n = 5 mice 
per group. 
 
